Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients (MIMOSA)

This study has been terminated.
(No benefit on primary end point (RFS); no rationale to collect survival data)
Information provided by (Responsible Party):
Menarini Group Identifier:
First received: January 4, 2007
Last updated: November 17, 2011
Last verified: November 2011
The purpose of this study is to evaluate the benefit of vaccination with Abagovomab, an experimental immunotherapy in ovarian cancer patients. The benefit will be evaluated in terms of time the remission status is kept as well as prolongation of life expectancy.

Condition Intervention Phase
Ovarian Cancer
Biological: Abagovomab
Biological: Placebo
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised,Double Blind, Placebo Controlled, Multicentre Trial of Abagovomab Maintenance Therapy in Patients With Epithelial Ovarian Cancer After Complete Response to First Line Chemotherapy

Resource links provided by NLM:

Further study details as provided by Menarini Group:

Primary Outcome Measures:
  • Recurrence Free Survival Evaluated by Clinical Event Adjudication Committee (CEAC) [ Time Frame: Every 12 weeks up to recurrence or up to 3 months after last administered dose ]
    The Recurrence free survival correspond to the time from date of randomization to documented disease recurrence or death. Disease recurrence is defined as the appearance of any lesion or development of tumor-related symptoms evaluated by medical examination and must be confirmed by a documented CT scan.

Secondary Outcome Measures:
  • Overall Survival [ Time Frame: 2 years ]
    2 years survival rate

  • Safety [ Time Frame: Along treatment administration and up to double blind observation period. i.e. for each patient after the first dose administration till the f inal study visit, or within 12 weeks of the last dose ]

    Safety was analyzed in all patients who received at least 1 dose administration.

    Adverse event (AE) are defined as events which started on or after the first dose of study medication and on or before the date of the final study visit, or within 12 weeks of the last dose if the final study visit was not performed.

  • Time Course of Immunoresponse [ Time Frame: at baseline, at week 10 after first dose administration and at final study visit (at week 4 or week 12 after the last administered dose, as appropriate) ]
    Time course of immunologic parameters (anti-anti-idiotypic antibody - Ab3) will be assessed in all patients, by comparing levels at baseline (week 0), at week 10 after first dose administration and at end of treatment (at week 4 or week 12 after the last administered dose, as appropriate).

Enrollment: 888
Study Start Date: December 2006
Study Completion Date: June 2011
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Abagovomab Biological: Abagovomab
2 mg/ml SC (subcutaneously)
Placebo Comparator: Placebo Biological: Placebo
2 mg/ml SC (subcutaneously)

Detailed Description:

Standard initial treatment of ovarian cancer patients includes both surgery and chemotherapy which in the vast majority of cases achieves the disappearance of ovarian cancer lesions. This status, called "clinical remission" which means having no evidence of cancer on CT scan or physical examination needs to be carefully follow up in order to confirm the maintenance of the remission status or to early detect if the cancer grows again and then start a new chemotherapy. At present, no approved therapies exist for the maintenance treatment of patients who achieved the clinical remission.

This trial aims to evaluate if the repeated vaccination with Abagovomab creates an immunoresponse which is able to fight the cancer cells thus keeping the remission status as long as possible and help patients live disease-free and longer.

Patients who achieve the remission status after chemotherapy will be screened for study participation and if they meet the criteria for inclusion they will start to receive a single subcutaneous injection every 2 weeks (for the first 4 doses - induction phase) and then every 4 weeks (maintenance phase). The duration of treatment is up to approximately 4 years or it will be stopped in case relapse occurs.

In order to evaluate the real benefit of vaccination, the experimental treatment includes Abagovomab (the active drug) or placebo (the vehicle only, without drug), with a double chance to receive Abagovomab. Assignment of Abagovomab or placebo will be done by a computerised system and nobody in the study will know which treatment has been allocated until study end.

Patients will be visited every 4 weeks and will undergo CT scan of pelvis and abdomen every 12 weeks in order to confirm the remission status or to early detect if relapse eventually occurs. This will be done in blind condition (i.e. without being aware which treatment the patient is going to receive) for the first part of the study which is expected to last four years. After then the overall status of patient will continue to be monitored by phone contact for additional five years.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

At a maximum of 12 weeks after the last cycle of first line standard platinum/taxane intravenous (IV) or intraperitoneal (IP) chemotherapy, patients must fulfill all the following inclusion criteria:

  • Age >/= 18 years;
  • Properly executed written informed consent;
  • History of histological and CA125 (> 35 U/ml) confirmed diagnosis of stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer;
  • History of debulking surgery and 6-8 cycles of standard platinum/taxane based non-investigational IV-IP chemotherapy;
  • Complete clinical response defined as:
  • Normal physical examination;
  • No symptoms suggestive of persistent cancer;
  • No definite evidence of disease by computed tomography (CT) of the abdomen and pelvis within the previous 4 weeks;
  • Negative chest x-ray (or chest CT scan) within the previous 4 weeks;
  • Serum CA125 within the normal laboratory range.
  • Adequate hematologic, renal and hepatic function:

    • Absolute Neutrophil Count (ANC) >/=1.5 * 109/l;
    • Platelets >/= 75 * 109/l;
    • Haemoglobin >/= 6.2 mmol/l (>9.9 g/dl);
    • Serum creatinine </= 1.5 * ULN (Upper Limit of Normal);
    • Bilirubin </= 1.5 * ULN; AST, ALT, AP </= 2.5 * ULN.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) </= 2.

Exclusion Criteria:

Patients are ineligible to participate in the study, if any of the following criteria are present:

  • any other invasive malignancies, with the exception of non-melanoma skin cancer or cervical carcinoma in situ, within the last 5 years or whose previous cancer treatment contraindicates this protocol therapy;
  • known active autoimmune disease requiring chronic treatment with immunosuppressive agents (e.g., rheumatoid arthritis, ulcerative colitis, etc.);
  • known immune deficiency (e.g. HIV, hypogammaglobulinemia, etc.);
  • known infection with hepatitis B, or hepatitis C;
  • history of recent myocardial infarction (</= 6 months) or decompensated heart failure (New York Heart Association - NYHA class >/= III);
  • previous or concomitant use of any anti-cancer therapy other than the platinum-taxane based 1st line chemotherapy for ovarian cancer; any maintenance or consolidation therapy is not permitted after completion of standard front line chemotherapy.
  • concomitant use of any other investigational agent;
  • any prior investigational anti-cancer vaccine or monoclonal antibody;
  • known allergy to murine proteins;
  • any significant medical or psychiatric condition, drug or alcohol abuse that might prevent the patient from complying with all study procedures;
  • clinically significant active infection;
  • concomitant use of any immunosuppressive agent (e.g., steroids, cyclosporin, etc.);
  • major surgery within the previous 2 weeks;
  • radiotherapy within the previous 4 weeks;
  • any significant toxicity from prior chemotherapy;
  • unreliability or inability to follow protocol requirements;
  • potentially childbearing and not willing to use adequate contraceptive methods throughout the entire study period;
  • pregnancy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00418574

  Show 150 Study Locations
Sponsors and Collaborators
Menarini Group
Study Chair: Jacobus Pfisterer, MD AGO-OVAR, Ovarian Cancer Study Group, Germany; Ubbo-Emmius-Klinik gGmbH Aurich, Germany
Principal Investigator: Paul Sabbatini, MD Memorial Sloan-Kettering Cancer Centre- NY
Principal Investigator: Jonathan Berek, MD COGI (Cooperative Ovarian Cancer Group for Immunotherapy); Dept Obstetrics and Gynecology, Stanford CA
Principal Investigator: Giovanni Scambia, MD Universtita' Cattolica del Sacro Cuore, Dipartimento di Oncologia - Roma, Italy
Principal Investigator: Antonio Casado, MD Hospital Clinico San Carlos, Servicio de Oncología Medica - Madrid, Spain
Principal Investigator: Anna Pluzanska, MD Klinika Chemioterapii Nowotworów Akademii Medycznej w Łodzi, Regionalny Osrodek Onkologiczny - Lodz, Poland
Principal Investigator: Karel Cwiertka, MD Onkologická klinika Fakultni Nemocnice Olomouc, Czech Republic
Principal Investigator: Tamás Pintér, MD Petz Aladar Megyei Oktató Kórház, Onkoradiológia - Győr, Hungary
Principal Investigator: Eric Pujade-Lauraine, MD Hôpital Hotel Dieu - Paris, France
  More Information


Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Menarini Group Identifier: NCT00418574     History of Changes
Other Study ID Numbers: ABA-01
AGO-OVAR 10 ( Other Identifier: AGO )
2006-002801-30 ( EudraCT Number )
Study First Received: January 4, 2007
Results First Received: July 1, 2011
Last Updated: November 17, 2011

Keywords provided by Menarini Group:
Ovarian cancer

Additional relevant MeSH terms:
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs processed this record on April 21, 2017